Direct Dose Equivalence Not Established
There is no established equivalent dose conversion between Vraylar (cariprazine) 1.5 mg and Abilify (aripiprazole), as these medications have different pharmacological profiles, receptor binding affinities, and clinical dose-response relationships that preclude direct milligram-to-milligram equivalency.
Why Direct Conversion Is Not Possible
Both cariprazine and aripiprazole are dopamine D2/D3 partial agonists, but they differ substantially in their pharmacodynamics:
- Cariprazine has preferential D3 receptor binding and an extremely long half-life (1-3 weeks for active metabolites), with therapeutic effects taking several weeks to fully manifest 1
- Aripiprazole has more balanced D2/D3 activity with a shorter half-life (approximately 75 hours)
- The maximum effective dose for cariprazine in treatment-resistant depression is 1.5 mg, while aripiprazole's maximum effective dose is 5.5 mg 2
Clinical Switching Approach
When switching between these D2 partial agonists, the 2025 INTEGRATE guidelines recommend:
Gradual cross-titration informed by the half-life and receptor profile of each medication 3. The guidelines specifically note that switching strategies should be individualized based on pharmacological properties rather than using fixed dose ratios.
Practical Switching Strategy
If switching from cariprazine 1.5 mg to aripiprazole:
- Start aripiprazole at 5-10 mg daily (typical therapeutic starting dose for most indications)
- Given cariprazine's extremely long half-life, active drug will persist for approximately 1 week after discontinuation 1
- Monitor closely for 2-4 weeks as cariprazine levels decline and aripiprazole reaches steady state
- Adjust aripiprazole dose based on clinical response (typical range 10-15 mg for schizophrenia, 5-15 mg for adjunctive depression)
Critical Caveats
- Do not assume 1:1 or any fixed ratio equivalence - these are fundamentally different medications despite being in the same class
- Cariprazine 1.5 mg represents a low-to-moderate therapeutic dose for most indications 1
- Aripiprazole dosing varies widely by indication (2-15 mg for adjunctive depression, 10-30 mg for schizophrenia)
- The prolonged washout period of cariprazine means clinical effects may persist or change gradually over weeks 1
Evidence-Based Context
Recent comparative data shows aripiprazole may have greater overall efficacy than cariprazine in treatment-resistant depression across the dose range, with aripiprazole 5.5-12.5 mg significantly outperforming all cariprazine doses 2. However, both medications demonstrated comparable clinical efficacy in schizophrenia when switched from olanzapine 4.
The bottom line: Base the aripiprazole dose on the clinical indication and patient response, not on attempting to "match" the cariprazine 1.5 mg dose.